The drug had earlier received the FDA’s breakthrough designation and orphan drug designation, making the application eligible for priority review. Efficacy was evaluated in CADENZA, a multicenter, open-label, single-arm clinical trial that included adult patients with treatment-naïve BPDCN (N=33) or relapsed or refractory BPDCN (N=51), without evidence of active central nervous system disease.